Baseline serum testosterone and differential efficacy of bipolar androgen therapy and enzalutamide in the randomized TRANSFORMER trial.

Mayuko Kanayama, Hua-Ling Tsai, Hao Wang, Emmanuel S Antonarakis, Samuel R Denmeade, Jun Luo

Abstract readRandomized Controlled Trial

In one paragraph

Trial report in Prostate cancer and prostatic diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mayuko KanayamaDepartment of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, 600N Wolfe St, Baltimore, MD, 21287, USA.

Hua-Ling TsaiDepartment of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 401N Broadway, Baltimore, MD, 21231, USA.

Hao WangDepartment of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 401N Broadway, Baltimore, MD, 21231, USA.

Emmanuel S AntonarakisDepartment of Oncology, Masonic Cancer Center, University of Minnesota Medical Center, 420 Delaware Street SE, MMC 480, Minneapolis, MN, 55455, USA.ORCID http://orcid.org/0000-0003-0031-9655

Samuel R DenmeadeDepartment of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, 600N Wolfe St, Baltimore, MD, 21287, USA.

Jun LuoDepartment of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, 600N Wolfe St, Baltimore, MD, 21287, USA. jluo2@jhmi.edu.ORCID http://orcid.org/0000-0002-1414-473X

Funding

Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Jeffrey S. Miller · 1998 to 2026

$100.4M

NCI NIH HHS P30 CA077598

6 · The paper itself

Abstract

Bipolar androgen therapy (BAT) is effective in a subset of metastatic castration-resistant prostate cancer (mCRPC) patients. Treatment selection biomarkers are needed due to other therapies that can be equally efficacious. We performed post-hoc analysis to determine whether baseline serum testosterone (T) is a treatment selection marker in the TRANSFORMER study, a randomized trial of abiraterone-pretreated mCRPC patients assigned to BAT (n = 94) or enzalutamide (n = 101). The findings suggest that patients with poor outcomes to abiraterone and serum T ≥ 20 ng/dL may benefit preferentially from BAT over enzalutamide. Baseline testosterone could be considered in the treatment selection process when BAT is an option.

Indexed as

AndrogensAntineoplastic Combined Chemotherapy ProtocolsPhenylthiohydantoinProstatic Neoplasms, Castration-ResistantTestosteroneAgedAndrostenesBenzamidesHumansMaleMiddle AgedNitrilesTreatment OutcomeabirateroneAndrogensAndrostenesBenzamidesenzalutamideNitrilesPhenylthiohydantoinTestosterone

Identifiers

PMID38714781

DOI10.1038/s41391-024-00844-w

PMCPMC12814870

What OpenQuestion holds

Textmetadata

LicenceTDM

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.